The State Food and Drug Administration issued the “30th Adverse Drug Reaction Information Bulletin” on the 22nd, reminding medical workers, drug manufacturers and the public to be alert to the risk of rhabdomyolysis caused by lamivudine and telbivudine. According to reports, lamivudine and tebivudine are both nucleoside antiviral drugs for the treatment of hepatitis B. The rhabdomyolysis is a class of diseases caused by the destruction and disintegration of the rhabdomyolus muscle, resulting in the entry of creatine kinase and other intracellular components into the extracellular fluid and blood circulation, causing disruption of the internal environment and acute renal failure, often caused by drugs, the manifestations of which are myalgia, weakness, elevated creatine kinase, elevated blood creatinine, etc. The briefing notes that rhabdomyolysis is a known adverse effect of lamivudine and telbivudine. Although the instructions for these two products have made such adverse reactions clear, the State Food and Drug Administration has issued another reminder to medical practitioners, drug manufacturers and the public in view of the fact that timely detection, diagnosis and treatment of this adverse reaction will benefit the prognosis of patients.